Efficacy and safety of teneligliptin.

about

Teneligliptin in Early Diabetic Kidney Disease: An Observation in Asian Indian Patients with Type 2 Diabetes Mellitus in Real-Life Scenario.Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.

P2860

Q38648862-58C163E3-D68A-4046-9BEA-CAC638488CD9 Q52594764-F6673BD5-BA92-4B84-AD0B-075772D1A498

P2860

Efficacy and safety of teneligliptin.

Item

http://www.wikidata.org/entity/Q42330154

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Efficacy and safety of teneligliptin.

@en

Efficacy and safety of teneligliptin.

@nl

type

Item

label

Efficacy and safety of teneligliptin.

@en

Efficacy and safety of teneligliptin.

@nl

prefLabel

Efficacy and safety of teneligliptin.

@en

Efficacy and safety of teneligliptin.

@nl

P1476

Efficacy and safety of teneligliptin

@en

P2093

Awadhesh Kumar Singh

http://www.w3.org/2001/XMLSchema#string

P2860

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor

A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited.

Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus

Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes

American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.

P304

11-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.4103/2230-8210.193163

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Awadhesh Kumar Singh

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28217491

http://www.w3.org/2001/XMLSchema#string

P932

5240050

http://www.w3.org/2001/XMLSchema#string

Efficacy and safety of teneligliptin.

about

P2860

P2860

Efficacy and safety of teneligliptin.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932